Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

EDCTP approves € 80 M of funding to boost HIV/AIDS, TB and malaria research

04.06.2008
The European & Developing Countries Clinical Trials Partnership (EDCTP) has approved over € 80 million for research into prevention of HIV/AIDS, tuberculosis and malaria in Africa. This sum is the highest amount of EDCTP funding approved to date. The approval marks an increase of European investment in research into the three poverty-related diseases and is expected to significantly enhance cooperation between European and African researchers.

EDCTP is a partnership of 14 European Member States plus Norway, Switzerland and sub-Saharan countries. The Partnership aims to reduce the global burden of HIV/AIDS, TB and malaria by pooling resources for conducting clinical trials in sub-Saharan Africa. The current approval of funding consists of a contribution from the European Commission of € 40 M, to be matched by European Member States and third parties. The projects involve 12 European countries and 22 sub-Saharan African countries. Funding was approved in the following areas:

Tuberculosis Vaccines
Malaria Treatment
Malaria in Pregnancy
Malaria Vaccines
Ethics review capacity
WHO regulatory affairs
Networks of Excellence
Senior Fellowships
Additional funding in the areas of HIV treatment, vaccines and microbicides, TB treatment and Networks of Excellence is expected to be approved in the second half of 2008.

The projects on TB and malaria that will be funded combine clinical trials with capacity building and networking activities. By integrating these activities EDCTP aims to enhance sustainability of conducting clinical trials on the African continent. A number of projects focuses on creating and developing capacity for ethics review of clinical trials and of enhancing the regulatory framework needed for approval of medicines in Africa. This enables African countries to conduct high-quality and ethically sound clinical trials, and to assess the safety and efficacy of all medicines that enter the African market.

EU Member State commitment and African leadership very encouraging
European Science and Research Commissioner Janez Potocnik underlined the integration of policies achieved by the partnership: "This decision from the EDCTP General Assembly shows the commitment of the participating countries and the European Commission in the fight against the three main poverty-related diseases in and for Africa. We're confident that our cooperation with African researchers will make a difference".

Prof. Charles Mgone, EDCTP’s executive director expressed the significance of the approval when he said: “This is a very significant milestone for collaboration between north and south in the fight against the three main diseases of poverty namely HIV/AIDS, tuberculosis and malaria. It is also very gratifying to note that among the 26 projects approved for funding 22 have African scientists based in Africa as their principal investigators. This underscores EDCTP’s objective of fostering a genuine partnership and enhancing clinical research capacity in Africa.”

About EDCTP
EDCTP aims through research integration to accelerate the development of new or improved drugs, vaccines, diagnostics and microbicides against HIV/AIDS, malaria and tuberculosis, with a focus on phase II and III clinical trials in sub-Saharan Africa.

EDCTP supports integrated multicentre projects which combine clinical trials, capacity building and networking. The aim of integrating these three activities is to develop the capacity to conduct clinical trials in sub-Saharan Africa in a sustainable way.

The basis of EDCTP is partnership. It unites 14 participating European Union (EU) Member States plus Norway and Switzerland with sub-Saharan African countries. The partnership helps EU Member States to integrate and coordinate their own national research and development programmes and form partnerships with their African counterparts.

Ilona van den Brink | alfa
Further information:
http://ec.europa.eu/research/index.cfm
http://www.edctp.org/index.php?id=428

More articles from Health and Medicine:

nachricht Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>